cancer vaccine news from FierceBiotech
News
GVAX questions depress Dendreon shares
After halting one GVAX study so it could further investigate a disturbing number of deaths, Cell Genesys' hopes for the vaccine are now focused on a separate Phase III trial that has not raised the Read more...
Deaths force halt to Cell Genesys cancer vaccine trial
A closely watched trial for Cell Genesys' prostate cancer vaccine GVAX was brought to a sudden halt after an independent monitoring committee noted a significantly higher death rate in the group Read more...
Kennedy's surgery may be followed by experimental therapy
Legendary Duke neurosurgeon Dr. Allan Friedman is scheduled to remove Senator Ted Kennedy's brain tumor this morning, and there's already significant speculation that the lawmaker will undergo Read more...
ALSO NOTED: FDA approves Orencia; Delay on Amgen clotting drug decision; Icahn files suit for Biogen Idec papers; and much more
> The FDA has approved Bristol-Myers Squibb's Orencia for juvenile arthritis. Read more...
Antigenics gets world's first cancer vaccine approval
Russia has improbably emerged as a world leader in new cancer vaccines. The country's regulatory body approved the use of Read more...
Oxford BioMedica benefits from TroVax results
Oxford BioMedica shares were boosted by the news that its first mid-stage trial of Read more...
Antigenics' cancer vax gets mixed Phase III results
Antigenics' cancer vaccine Oncophage failed to meet its primary endpoint of overall Read more...
Is Sanofi preparing a bid for Oxford BioMedica?
Investors have focused their attention on Oxford BioMedica, a struggling UK developer that is the Read more...
Rumor Mill: Sanofi to buy Oxford BioMedica
Rumors are swirling that Sanofi-Aventis may be making a bid for Oxford BioMedica, a U.K.-based developer of gene-based medicines. Oxford's shares have surged in response to a report published in The Read more...
SPOTLIGHT: Geron gains milestone from Merck
Merck has filed an IND for a cancer vaccine candidate that targets telomerase, triggering a $4 million milestone payment to licensing partner Geron. Read more...
Get more cancer vaccine coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets